N/A N=13 High-Risk Neuroblastoma Chemotherapy Without G-CSF
Neuroblastoma
Primary: Incidence of Infection — 6 infections
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=13 Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma
Neuroblastoma
Primary: Response Rate Associated With Two Cycles of Cisplatin With Protracted Oral Etoposide When Administered as Up-front Window Therapy to Previously Untreated Children With…
Phase 2 N=64 Therapy for Children With Advanced Stage Neuroblastoma
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Phase 2 N=34 Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Neuroblastoma
Primary: Overall Responses — 3; 18; 12; 1 Participants
Phase 3 N=464 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
Neuroblastoma
Primary: Overall Survival (OS) Rates — 99.4; 93.5; 88.4 percentage of participants
Phase 3 N=105 Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma
High Risk Neuroblastoma
Primary: Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome…
Phase 2 N=48 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Pancreatic Cancer · Pancreatic Adenocarcinoma · Pancreas Ductal Adenocarcinoma
Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC
Phase 1 N=5 Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma
Neuroblastoma
Primary: Number of Participants With Immediate and Short Term Toxicity of Infusion Over 8 Weeks — 0; 0; 3 Participants
Phase 3 N=1,449 Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Localized Resectable Neuroblastoma · Localized Unresectable Neuroblastoma · Recurrent Neuroblastoma
Primary: Event-Free Survival (EFS) — 48.1; 62.9 Percentage of participants — p=0.1016
Phase 3 N=665 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
Localized Resectable Neuroblastoma · Localized Unresectable Neuroblastoma · Recurrent Neuroblastoma
Primary: Event-free Survival Rate — 48.8; 61.8 percent probability — p=0.0082
Phase 1 N=12 Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
High Risk Neuroblastoma · Recurrent Neuroblastoma · Recurrent Osteosarcoma
Primary: Percent (95% CI) of Participants With Grade 3 or Higher Adverse Events (Dose Finding Cohort) — 71.4; 100 percentage of participants
Phase 2 N=42 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Ganglioneuroblastoma · High Risk Neuroblastoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0.0 percentage of patients
Phase 2 N=44 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Neuroblastoma · Sarcoma · Rhabdomyosarcoma-Embryonal
Primary: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay — 0; 15 Participants — p=0.043
Phase 2 N=73 Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Ganglioneuroblastoma · Recurrent Neuroblastoma
Primary: Percentage of Randomized Patients Who Are Responders — 5.6; 52.9 Percentage of patients
Phase 1 N=18 TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Neuroblastoma · Medulloblastoma · Relapse
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 14 participants